Table 1.
Inhibition of Human Metabolic Enzymes by Exogenous Cannabinoids In Vitro and the Extrapolated Levels of Oral Daily CBD Administration in Humans Needed to Reach These In Vitro Concentrations (Adapted)6,8
| CYP-450 isoform | 1A1 | 1A2 | 1B1 | 2A6 | 2B6 | 2C9 | 2D6 | 3A4 | 3A5 | 3A7 |
|---|---|---|---|---|---|---|---|---|---|---|
| CBD (in μM) | 0.2 | 2.7 | 3.6 | 55.0 | 0.7 | 0.9–9.9 | 1.2–2.7 | 1.0 | 0.2 | 12.3 |
| aExtrapolated oral daily CBD doses to reach the levels above (in mg) | 4900 | 63,000 | 84,000 | 1.28 Mio. | Ca. 16,000 | 21,000–231,000 | 28,000–63,000 | Ca. 23,000 | 4900 | 0.29 Mio. |
a
The calculations made here are based on the assumption that the CBD distribution in the blood follows the pharmacokinetics of a hydrophilic substance such as alcohol. The reality is more complex, because CBD is lipophilic and, for example, will consequently accumulate in fat tissue. These calculations were made with the intention to give the reader an impression and an approximation of the supraphysiological levels used in in vitro studies.